Acute Lymphocytic Leukemia Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The report covers Acute Lymphoblastic Leukemia Therapeutics Market Statistics and it is segmented by Type of Cell, Type of Therapy (Chemotherapy, Targeted Therapy, Radiation Therapy, Stem Cell Transplantation), and Geography. The market provides the value (in USD million) for the above-mentioned segments.

Acute Lymphoblastic Leukemia Therapeutics Market Size

Single User License
Team License
Corporate License
Book before:
share button
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR 5.20 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players


*Disclaimer: Major Players sorted in no particular order


Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License


Team License


Corporate License

Book before:

Acute Lymphoblastic Leukemia Therapeutics Market Analysis

One of the major factors responsible for the growth of this market includes the rising occurrence of acute lymphoblastic leukemia (ALL) globally. The number of new cases being recorded each year is around 1.7 per 100,000 men and women per year. It has been estimated by the American Cancer Institute that in 2019, there will be around 5,930 new cases of ALL i.e. 3,280 in males and 2,650 in females. In addition, by 2020, it has been estimated that the number of cases of ALL may range around 0.4 to 2 per 100,000 population in the Asia-Pacific and South American countries.

There is a rise in the number of cases primarily due to the adoption of western lifestyles, including dietary changes and sedentary lifestyles. Moreover, globally, the prevalence is expected to increase during the forecast period, which shall be the major factor for the growth of this market.

Acute Lymphoblastic Leukemia Therapeutics Market Trends

This section covers the major market trends shaping the Acute Lymphoblastic Leukemia Therapeutics Market according to our research experts:

Chemotherapy is Expected to Dominate the Type of Therapy Segment

The American Cancer Association stated that chemotherapy is the main treatment for the people suffering from acute lymphoblastic leukemia (ALL), and it has three phases, such as remission, consolidation, and maintenance. Chemotherapy uses cytotoxic drugs for the destruction of cancer cells.

Amsacrine (NordMedica), cyclophosphamide (Baxter), and cytarabine (Pfizer) are some of the drugs that are used for chemotherapy in ALL. Global pharmaceutical players, such as Baxter International, and Pfizer, are providing these drugs. ALL is the most common cancer in children, adolescents, and young adults younger than 20 years, accounting for 19.8% of all cancer cases in this age group, as per a 2019 report by the Leukemia & Lymphoma Society. Hence, the market for chemotherapy is also expected to boost due to high prevalence of ALL, especially among children.


North America to Dominate the Market Over the Forecast Period

North America is expected to dominate this market, due to the rising number of cases of this disease in the region, owing to genetic factors, environmental factors, and radiation. Moreover, favorable government policies, well-established healthcare infrastructure, and the presence of multinational companies make this region dominant in this market. 

Asia-Pacific is also expected to register a high CAGR during the forecast period, owing to several factors, such as high unmet clinical needs, huge patient pool, and the rising awareness about early diagnosis in emerging countries.


Acute Lymphoblastic Leukemia Therapeutics Industry Overview

The market for acute lymphoblastic leukemia is moderately competitive and consists of the big players as well as the mid-sized companies. Owing to the rising focus of most of the pharmaceutical companies on oncology, it is expected that few new small-sized companies will also penetrate the market in the near future.

Acute Lymphoblastic Leukemia Therapeutics Market Leaders

  1. Pfizer Inc.

  2. Bristol-Myers Squibb Company

  3. Novartis AG

  4. SymBio Pharmaceuticals Limited

  5. Genmab AS

*Disclaimer: Major Players sorted in no particular order

leukemia therapeutics market
bookmark Need More Details on Market Players and Competitors?
Download PDF

Acute Lymphoblastic Leukemia Therapeutics Market Report - Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rise in the Incidences of Acute Lymphoblastic Leukemia

      2. 4.2.2 Increasing Initiatives Taken by the Government and Private Organizations

    3. 4.3 Market Restraints

      1. 4.3.1 Stringent Regulatory Pathways

      2. 4.3.2 High Cost Asscoiated with the Treatment

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Type of Cell

      1. 5.1.1 B-cell ALL

      2. 5.1.2 T-cell ALL

      3. 5.1.3 Philadelphia Chromosome: Positive (Ph+) and Negative (Ph-) ALL

    2. 5.2 By Type of Therapy

      1. 5.2.1 Chemotherapy

        1. Hyper - CVAD Regimen

        2. CALGB 8811 Regimen

        3. Linker Regimen

        4. Nucleoside Inhibitors

        5. Other Types of Therapies

      2. 5.2.2 Targeted Therapy

      3. 5.2.3 Radiation Therapy

      4. 5.2.4 Stem Cell Transplantation

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle East & Africa

        1. GCC

        2. South Africa

        3. Rest of Middle East & Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Bristol Myer Squibb Company

      2. 6.1.2 Celegene Corporation

      3. 6.1.3 Eisai Co Ltd

      4. 6.1.4 Erytech Pharma

      5. 6.1.5 F. Hoffmann-La Roche Ltd

      6. 6.1.6 Genmab A/S

      7. 6.1.7 GlaxoSmithKline PLC

      8. 6.1.8 Novartis AG

      9. 6.1.9 Pfizer Inc.

      10. 6.1.10 Sanofi SA

    2. *List Not Exhaustive

**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments
bookmark You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Acute Lymphoblastic Leukemia Therapeutics Industry Segmentation

As per the scope of the report, acute lymphoblastic leukemia (ALL), also called lymphoblastic leukemia, is one of the most common types of cancer, which spreads in the body through lymph nodes, spinal cord, liver, spleen, and central nervous system, among others. B-cell ALL, T-cell ALL, and Philadelphia chromosome-positive ALL (Ph+ ALL) are three of the most common primary types of ALL. B-cell ALL is the most common type. The treatment of patients with Ph+ ALL involves precise drugs that target the gene products.

By Type of Cell
B-cell ALL
T-cell ALL
Philadelphia Chromosome: Positive (Ph+) and Negative (Ph-) ALL
By Type of Therapy
Hyper - CVAD Regimen
CALGB 8811 Regimen
Linker Regimen
Nucleoside Inhibitors
Other Types of Therapies
Targeted Therapy
Radiation Therapy
Stem Cell Transplantation
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle East & Africa
South Africa
Rest of Middle East & Africa
South America
Rest of South America
customize-icon Need A Different Region Or Segment?
Customize Now

Acute Lymphoblastic Leukemia Therapeutics Market Research FAQs

The Acute Lymphoblastic Leukemia Therapeutics Market is projected to register a CAGR of 5.20% during the forecast period (2024-2029)

Pfizer Inc., Bristol-Myers Squibb Company, Novartis AG, SymBio Pharmaceuticals Limited and Genmab AS are the major companies operating in the Acute Lymphoblastic Leukemia Therapeutics Market.

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).

In 2024, the North America accounts for the largest market share in Acute Lymphoblastic Leukemia Therapeutics Market.

The report covers the Acute Lymphoblastic Leukemia Therapeutics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Acute Lymphoblastic Leukemia Therapeutics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.

Acute Lymphocytic Leukemia Therapeutics Industry Report

Statistics for the 2024 Acute Lymphocytic Leukemia Therapeutics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Acute Lymphocytic Leukemia Therapeutics analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!

Acute Lymphocytic Leukemia Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)